

*The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 25 May 2023 at 07.00 under RNS No 5813A.*

*Jonathan Glenn's beneficial holding (including the interests of his Persons Closely Associated) represents 0.14% of the total voting rights in the Company's share capital.*

*All other details remain unchanged. The full amended text is shown below.*

**Surgical Innovations Group plc**  
("Surgical Innovations", "SI" or the "Company")

### **Director/PDMR Shareholding**

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), was notified on 24 May 2023 that, on 24 May 2023, Janis Glenn (wife of Jonathan Glenn, Non-executive Director) purchased 1,315,482 ordinary shares of 1p each in Surgical Innovations ("Ordinary Shares") at a price of 2.28 pence per share.

Following this transaction, Jonathan Glenn (including his Persons Closely Associated) has a beneficial holding in the Company of 1,315,482 Ordinary Shares, representing approximately 0.14% of the issued share capital of the Company.

#### **For further information please contact:**

**Surgical Innovations Group plc**  
David Marsh, CEO  
Charmaine Day, CFO

[www.sigroupplc.com](http://www.sigroupplc.com)  
Tel: 0113 230 7597

**Singer Capital Markets (Nominated Adviser & Broker)**  
Aubrey Powell / Oliver Platts

**Tel: 020 7496 3000**

**Walbrook PR (Financial PR & Investor Relations)**  
Paul McManus / Lianne Applegarth

**Tel: 020 7933 8780 or [si@walbrookpr.com](mailto:si@walbrookpr.com)**  
Mob: 07980 541 893 / 07584 391 303

|    |   |                                |
|----|---|--------------------------------|
|    | Details of the person discharging managerial responsibilities/person closely associated   |                                |
| a) | Name  | Jonathan Glenn                 |
| 2  | Reason for the notification   |                                |
| a) | Position/status   | Non-executive Director         |
| b) | Initial notification/ Amendment   | Initial Notification           |
| 3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor   |                                |
| a) | Name  | Surgical Innovations Group plc |
| b) | LEI   | 2138004GHGUH3HUZE156           |
| 4  | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |                                |
| a) | Description of the financial instrument, type of instrument   | Ordinary shares of 1p          |

|    |  |                             |           |
|----|--|-----------------------------|-----------|
|    | Identification code                                      | GB0004016704                |           |
| b) | Nature of the transactions                               | Purchase of Ordinary Shares |           |
| c) | Price(s) and volume(s)                                   | Price(s) per share          | Volume(s) |
|    |  | 2.28 pence                  | 1,315,482 |
| d) | Aggregated information<br>- Aggregated volume<br>- Price | 1,315,482<br>2.28p          |           |
| e) | Date of the transaction                                  | 24 May 2023                 |           |
| f) | Place of the transaction                                 | London Stock Exchange, AIM  |           |

### **About Surgical Innovations Group plc**

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.

### **Further information**

Further details of the Group's businesses and products are available on the following websites:

[www.sigroupplc.com](http://www.sigroupplc.com)

[www.surginno.com](http://www.surginno.com)

[www.elementalhealthcare.co.uk](http://www.elementalhealthcare.co.uk)

To receive regular updates by email, please contact [sj@walbrookpr.com](mailto:sj@walbrookpr.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHAAMMTMTMTB RJ